At Axol, we’re here to support drug discovery researchers who want to harness the power of iPSC-derived models. Like you, we believe that these more human-relevant advanced in vitro models have the potential to unlock better, safer therapies for neurodegenerative and cardiovascular diseases.
We’ve been working with iPSCs in a quality-focused environment for over a decade and have developed a deep understanding of the challenges of this space. Whether it’s compound screening on physiologically useful models, iPSC creation, QC and banking, or the large-scale supply of functionally-relevant cells, we can help you.
Our capabilities include:
High-quality, functionally consistent axoCellsTM, a bank of over 70 fully characterized and licensed axoLinesTM, our QC-rich axoServicesTM, and the ability to work with you to build, validate and use iPSC-based axoModelsTM.
Collaboration is one of our six core company values; we’re here to help you by doing the heavy lifting, so you can focus on the science with reduced risk, shortened project timelines and improved outcomes.
